The Society for Immunotherapy of Cancer’s (SITC) 35th Anniversary Annual Meeting & Pre-Conference Programs (SITC 2020) will be reimagined as a fully VIRTUAL experience this year to ensure the health and safety of program attendees and their patients, and in celebration of the society’s 35th anniversary, all SITC members are invited to register for FREE!
The conference includes cutting-edge research presented by experts in the field, oral and poster abstract presentations, and ample opportunity for structured and informal discussions, including networking opportunities. Attendees participate in a variety of basic-, translational- and clinical-focused concurrent sessions and are updated about national and international initiatives from academia, government and industry, and other important SITC projects.
This Anniversary Annual Meeting will feature special programming and events in recognition of the society's ongoing commitment to harnessing the immune system for 35 years to transform cancer outcomes.
35th Anniversary Annual Meeting Organizers
- Helen E. Heslop, MD – Baylor College of Medicine
- Brianna W. Hoffner, MSN, ANP-BC, AOCNP – Harborside
- Miriam Merad, MD, PhD – Icahn School of Medicine at Mount Sinai
- Padmanee Sharma, MD, PhD – The University of Texas MD Anderson Cancer Center
- Jedd D. Wolchok, MD, PhD – Memorial Sloan Kettering Cancer Center
Annual Program Committee
- Chair: Sandra Demaria, MD – Weill Cornell Medicine
- Ana Carrizosa Anderson, PhD – Harvard Medical School
- Davide Bedognetti, MD, PhD – Sidra Medicine
- Marianne Davies, DNP, AOCNP – Yale School of Nursing
- Patrick Hwu, MD – Moffitt Cancer Center
35th Anniversary Annual Meeting Schedule
To view the Annual Meeting's full schedule, please click here.
SITC's 35th Anniversary Annual Meeting is supported in part by grants from Adaptive Biotechnologies, Alkermes, Amgen, AstraZeneca Pharmaceuticals LP, Bayer, Bristol Myers Squibb, Exelixis, Inc., Incyte Corporation, Iovance Biotherapeutics, Janssen Research & Development, LLC, Kite, a Gilead Company, Novartis Pharmaceuticals, Pfizer, Inc., and Regeneron Pharmaceuticals.
The audience includes basic and clinical investigators from academic institutions, industry and regulatory agencies, including clinicians, basic and translational researchers, graduate students, post-doctoral fellows, and allied health professionals involved in cancer research as well as pharmacists and payers, who wish to learn more about cancer immunology and immunotherapy and its incorporation into current (and future) effective cancer treatment
At the conclusion of this activity, participants should be able to:
Summarize and integrate the most recent advances in tumor immunology and cancer immunotherapy into basic, clinical and translational research
Analyze cutting-edge clinical trials to incorporate new research and techniques into clinical applications for cancer immunotherapy
Describe immune regulatory pathways that restrict and enhance immunity to tumor antigens, and identify respective targets for therapeutic intervention
SITC 2020 focuses broadly on all areas of cancer immunotherapy and tumor immunology including:
- Cellular Therapy
- Checkpoint Inhibitors
- Combination treatments
- Immune Agonists
- Immune Conjugates
- Intratumoral therapies
- Oncolytic Viruses
- Clinical management
- Clinical trials
- Gene editing
- Immune cell biology
- Preclinical studies
- Regulatory considerations
- Response mechanisms
- Tumor biology
This program will be accredited to offer CME, CNE, CPE and MOC credits.